+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Escherichia coli Infections - Pipeline Review, H2 2019

  • ID: 4901293
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 202 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • ContraFect Corp
  • Forge Therapeutics Inc
  • Meiji Seika Pharma Co Ltd
  • Northern Antibiotics Oy
  • Protein Potential LLC
  • MORE
Escherichia coli Infections - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H2 2019, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 31 and 18 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 7 and 13 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • ContraFect Corp
  • Forge Therapeutics Inc
  • Meiji Seika Pharma Co Ltd
  • Northern Antibiotics Oy
  • Protein Potential LLC
  • MORE
Introduction
Report Coverage
Escherichia coli Infections - Overview
Escherichia coli Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Escherichia coli Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Escherichia coli Infections - Companies Involved in Therapeutics Development
ABAC Therapeutics SA
Abgentis Ltd
Affilogic SAS
AstraZeneca Plc
Atterx Biotherapeutics Inc
BB100 LLC
Biomendics LLC
Bugworks Research India Pvt Ltd
ContraFect Corp
Curza Global LLC
Debiopharm International SA
Eligo Bioscience SA
Eligochem Ltd
EnBiotix Inc
EveliQure Biotechnologies GmbH
F. Hoffmann-La Roche Ltd
Forge Therapeutics Inc
GlyProVac ApS
Hsiri Therapeutics LLC
Immuron Ltd
Johnson & Johnson
Kyorin Pharmaceutical Co Ltd
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Navigen Inc
Neoculi Pty Ltd
Northern Antibiotics Oy
Nosopharm SAS
Novabiotics Ltd
Oxford Drug Design Ltd
Paratek Pharmaceuticals Inc
Phico Therapeutics Ltd
Procarta Biosystems Ltd
Protein Potential LLC
Pylum Biosciences Inc
Recce Ltd
RemAb Therapeutics SL
Sealife PHARMA GMBH
Shanghai Space Peptides Pharmaceutical Co Ltd
Soligenix Inc
Spero Therapeutics Inc
Syntiron LLC
TCM Biotech International Corp
Tetraphase Pharmaceuticals Inc
Venus Medicine Research Center
Escherichia coli Infections - Drug Profiles
Escherichia coli Infections - Dormant Projects
Escherichia coli Infections - Discontinued Products
Escherichia coli Infections - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Escherichia coli Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Escherichia coli Infections - Pipeline by ABAC Therapeutics SA, H2 2019
Escherichia coli Infections - Pipeline by Abgentis Ltd, H2 2019
Escherichia coli Infections - Pipeline by Affilogic SAS, H2 2019
Escherichia coli Infections - Pipeline by AstraZeneca Plc, H2 2019
Escherichia coli Infections - Dormant Projects, H2 2019
Escherichia coli Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
Escherichia coli Infections - Dormant Projects, H2 2019 (Contd..2), H2 2019
Escherichia coli Infections - Dormant Projects, H2 2019 (Contd..3), H2 2019
Escherichia coli Infections - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Escherichia coli Infections, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ABAC Therapeutics SA
  • Abgentis Ltd
  • Affilogic SAS
  • AstraZeneca Plc
  • Atterx Biotherapeutics Inc
  • BB100 LLC
  • Biomendics LLC
  • Bugworks Research India Pvt Ltd
  • ContraFect Corp
  • Curza Global LLC
  • Debiopharm International SA
  • Eligo Bioscience SA
  • Eligochem Ltd
  • EnBiotix Inc
  • EveliQure Biotechnologies GmbH
  • F. Hoffmann-La Roche Ltd
  • Forge Therapeutics Inc
  • GlyProVac ApS
  • Hsiri Therapeutics LLC
  • Immuron Ltd
  • Johnson & Johnson
  • Kyorin Pharmaceutical Co Ltd
  • Linnaeus Bioscience Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • Navigen Inc
  • Neoculi Pty Ltd
  • Northern Antibiotics Oy
  • Nosopharm SAS
  • Novabiotics Ltd
  • Oxford Drug Design Ltd
  • Paratek Pharmaceuticals Inc
  • Phico Therapeutics Ltd
  • Procarta Biosystems Ltd
  • Protein Potential LLC
  • Pylum Biosciences Inc
  • Recce Ltd
  • RemAb Therapeutics SL
  • Sealife PHARMA GMBH
  • Shanghai Space Peptides Pharmaceutical Co Ltd
  • Soligenix Inc
  • Spero Therapeutics Inc
  • Syntiron LLC
  • TCM Biotech International Corp
  • Tetraphase Pharmaceuticals Inc
  • Venus Medicine Research Center
Note: Product cover images may vary from those shown
Adroll
adroll